Depression CRO Findings
Transpharmation has developed a platform of sensitive and highly consistent TRD preclinical assays responsive to ketamine. The chronic social defeat (CSD) mouse model has high construct, face and predictive validity and is sensitive to the effects of ketamine, providing a potential means to investigate the basic neuropathology underlying affective illnesses such as anxiety and TRD.
Our EEG platform has demonstrated robust differences in the sleep/wake profiles of Wistar Kyoto rats, (an endogenous model of depression) versus Sprague Dawley controls, which are also normalised by ketamine treatment. Furthermore, the cognitive symptoms of depression, including working memory deficits, can also be modelled using WKY rats, with ketamine again demonstrating efficacy. Our behavioural end points can be coupled with biomarker analysis to investigate the neurobiology of the disease and facilitate decision making.
This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.